UBS Group
CGON icon

UBS Group’s CG Oncology CGON Stock Holding History

UBS Group’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.8M Sell
1,311,978
-611,768
-32% -$34.7M 0.01% 1141
2025
Q4 		$79.9M Sell
1,923,746
-202,524
-10% -$8.38M 0.01% 1194
2025
Q3 		$85.6M Sell
2,126,270
-102,975
-5% -$2.99M 0.01% 1145
2025
Q2 		$58M Buy
2,229,245
+524,527
+31% +$12.6M 0.01% 1378
2025
Q1 		$41.7M Buy
1,704,718
+690,827
+68% +$19.4M 0.01% 1646
2024
Q4 		$29.1M Buy
1,013,891
+927,357
+1,072% +$31.7M 0.01% 1947
2024
Q3 		$3.26M Buy
86,534
+8,454
+11% +$296K ﹤0.01% 3500
2024
Q2 		$2.46M Buy
78,080
+54,757
+235% +$1.9M ﹤0.01% 3553
2024
Q1 		$1.02M Buy
+23,323
New +$953K ﹤0.01% 4583

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's CGON Position: Q1 2026 in Review

UBS Group reduced its CG Oncology (CGON) stake by 32% in Q1 2026, selling an estimated $34.7M and leaving 1,311,978 shares worth $88.8M. The position accounts for 0.01% of the portfolio, ranked #1141.

UBS Group first reported a position in CGON in Q1 2024 and has held it in 9 quarters since. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • UBS Group held 1,311,978 shares of CG Oncology worth $88.8M as of Q1 2026.
  • UBS Group sold 611,768 CG Oncology shares in Q1 2026, an estimated $34.7M.
  • CG Oncology made up 0.01% of UBS Group's portfolio in Q1 2026, its #1141 holding.
  • UBS Group first reported a position in CG Oncology in Q1 2024 and has held it in 9 quarters since.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.